Powder: -20°C for 3 years | In solvent: -80°C for 1 year
E3330 是一种口服有效的选择性 AP 内切核酸酶 1 (APE1; REF-1) 抑制剂,可抑制NF-κB DNA 结合活性。它阻断 TNF-α 诱导的肝癌细胞系中 IL-8 的激活,可以抑制癌细胞的生长和迁移,具有抗癌活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 428 | 现货 | ||
2 mg | ¥ 617 | 现货 | ||
5 mg | ¥ 938 | 现货 | ||
10 mg | ¥ 1,610 | 现货 | ||
25 mg | ¥ 2,890 | 现货 | ||
50 mg | ¥ 4,270 | 现货 | ||
100 mg | ¥ 5,970 | 现货 | ||
200 mg | ¥ 8,380 | 现货 | ||
500 mg | ¥ 12,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 798 | 现货 |
产品描述 | E3330 is a potent and selective APE1(Ref-1) inhibitor, which suppressed NF-kappa B DNA-binding activity. |
体外活性 | E3330 affects hemangioblast development in vitro via inhibition of Ape1 redox activity. [1] E3330 inhibits the growth of human pancreatic cancer cell line PANC1, XPA1, MIAPACA, BxPC3, and PK9. E3330 also promotes exit of cell cycle in PANC1 cells, inhibits the DNA-Binding activity of HIF-1α and migration of pancreatic cancer cells. [2] In JHH6 cells, E3330 prevents the functional activation of NF-κB via the alteration of APE1 subcellular trafficking and reduces IL-6 and IL-8 expression induced by TNF-α and FAs accumulation through blockage of the redox-mediated activation of NF-κB. [3] |
体内活性 | In mice with endotoxin-mediated hepatitis, E3330 (300 mg/kg, p.o.) attenuates the elevation of plasma tumor necrosis factor activity and protectes mice from liver injury. [4] In Rat model, E3330 (100 mg/kg, p.o.) also protectes rats from severe liver injury induced with endotoxin plus galactosamine. [5] |
细胞实验 | PANC1 cells are placed in one well of a 12-well plate and treated with 5 to 30 μM E3330. After a 24, 48, and 72 h of culture, the cells are washed with PBS and stained with trypan blue, and cell viability is examined by counting the live cell numbers.(Only for Reference) |
分子量 | 378.46 |
分子式 | C21H30O6 |
CAS No. | 136164-66-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 70 mg/mL (185 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 70 mg/mL (185 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.6423 mL | 13.2114 mL | 26.4229 mL | 66.0572 mL |
5 mM | 0.5285 mL | 2.6423 mL | 5.2846 mL | 13.2114 mL | |
10 mM | 0.2642 mL | 1.3211 mL | 2.6423 mL | 6.6057 mL | |
20 mM | 0.1321 mL | 0.6606 mL | 1.3211 mL | 3.3029 mL | |
50 mM | 0.0528 mL | 0.2642 mL | 0.5285 mL | 1.3211 mL | |
100 mM | 0.0264 mL | 0.1321 mL | 0.2642 mL | 0.6606 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
E3330 136164-66-4 Cell Cycle/Checkpoint Chromatin/Epigenetic DNA Damage/DNA Repair Metabolism HIF/HIF Prolyl-Hydroxylase DNA/RNA Synthesis pancreatic cancer TNF-α REF-1 NF-κB HIFs Inhibitor HIF-PH Nuclear factor-kappaB APX-3330 APE1 APX 3330 NSCLC cells neuroprotective APX3330 E-3330 endonuclease VEGFR EPCs AP-1 HUVECs Nuclear factor-κB Reactive Oxygen Species E 3330 DNA-binding Activator Protein 1 Hypoxia-inducible factors orally PANC1 anticancer H1975 PCECs inhibit IL-8 Vascular endothelial growth factor receptor inhibitor